Welsh government funds GSK's Bexsero; Weber says Takeda turnaround involves vaccines focus;

> The Welsh government has agreed to fund GlaxoSmithKline's ($GSK) meningitis B vaccine Bexsero for every baby in the country at a cost of £7.7 million. Report

> Shortly after becoming Takeda CEO, Christophe Weber said the turnaround there has quickened, with a renewed focus on generics, emerging markets and vaccines. Report

> Two novel Ebola vaccines protected macaques against the strain of the virus responsible for the deadly outbreak with no side effects. Story (reg. req.)

> Samsung Pharmaceutical agreed to manufacture and sell GemVax & KAEL Co.'s pancreatic cancer vaccine Rivavax in South Korea until 2020 for 5 billion won ($4.5 million). Report

> Merck ($MRK) and Advaxis ($ADXS) announced enrollment in a Phase I/II study of prostate cancer vaccine ADXS-PSA. in combination with Merck's Keytruda. Release

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.